fbpx

Dr. Muraleedharan, Associate Research Scientist in the Department of Therapeutic Radiology
at Yale School of Medicine (YSM), will assess whether a NAMPT inhibitor-based treatment
strategy will be effective against DIPG. With this project, he will with test specific targeted
inhibitors in combination with radiation therapy and DNA damaging therapies that are already
used in the clinic for glioma treatment. He aims to move his therapy into clinical trials within 3
years.

“DIPG represents a significant unmet need in childhood cancer treatments, and we’re proud to
support a project that could change the odds for the kids facing this grim diagnosis” said Oscar
Ortiz, Executive Director and Co-founder of SebastianStrong.

Dr. Muraleedharan’s mentor, Dr. Ranjit Bindra, Professor of Therapeutic Radiology at YSM, is a
current CureSearch Catapult awardee who used a similar approach to move a new therapy from
discovery to clinical trial in under two years.

This project is supported via the SebastianStrong Discovery Award

Pin It on Pinterest

Scroll to Top